New York City-based Mount Sinai has implemented an FDA-approved AI tool designed to improve detection of congenital heart defects in fetal ultrasounds.
The Carnegie Imaging for Women, a Mount Sinai-affiliated OB-GYN imaging facility, became the first center in New York City to adopt the AI software from BrightHeart. Researchers at Mount Sinai West used the tool to assess 200 de-identified ultrasound scans from 11 medical centers across two countries, according to a Dec. 2 news release from the health system.
Use of the AI tool led to improved detection of major congenital heart defects in more than 97% of cases, with an 18% reduction in scan reading time and a 19% increase in confidence scores. Seven OB-GYNs and seven maternal-fetal medicine specialists participated in the study, evaluating the scans both with and without AI assistance.
The software is designed to identify second-trimester ultrasound findings suspicious for severe congenital heart defects, which affect about 1 in 500 newborns and often require urgent medical or surgical intervention, the release said.
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
